Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms.
In 2008, total sales of prescription and OTC smoking cessation products amounted to over $3bn worldwide. Smoking Cessation, 2009-2024 forecasts how this market will grow and develop from 2009 to 2024. Visiongain predicts that launches of nicotine vaccines from 2011 onwards will alleviate some of the currently-unmet needs in smoking cessation. Which nicotine vaccine will be first to market? Smoking Cessation, 2009-2024 answers that question and many others, providing expert-opinion and analyses on the development of smoking cessation products of many types, dealing with both pipeline and marketing developments in the sector.
During the next 15 years, overall growth in the world smoking cessation market will be increasingly contributed by the BRIC (Brazil, Russia, India and China) group of countries. Nearly half of the world’s smokers live in BRIC areas, yet those country markets yielded low per capita smoking cessation revenues in 2008. Smoking Cessation, 2009-2024 analyses the BRIC smoking cessation markets and their prospects for future growth, revealing how their market shares will increase from 2009 to 2024. This report also analyses the current-leading markets in North America, Europe and Asia in detail.
Smoking Cessation, 2009-2024 is a comprehensive analysis of the world smoking cessation market, compiled using a wealth of research tools - including interviews with key opinion-leaders, examination of company reports, press-releases and filings, use of commercial databases and analyses of unmet needs and market opportunities. Highlights include:
Forecasts for the world smoking cessation market, leading therapy types, brands and individual country markets.
Detailed examination and market forecasts for the individual country smoking cessation markets in the US, Canada, Brazil, the UK, France, Germany, Sweden, Russia, Japan, China and India.
Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the industry.
In-depth analysis of the pharmacological pipeline for new smoking cessation products.
Why you should buy this report:
To receive a comprehensive analysis of the prospects for smoking cessation therapies from 2009-2024, including predicted revenues, growth rates and other key metrics.
To discover the fate of Pfizer’s Chantix/Champix, in light of recent safety-concerns.
To identify key pipeline developments and up-and-coming products.
To discover the forces, restraints, competition and opportunities influencing each of the separate areas of the smoking cessation market, including nicotine replacement therapies, Pfizer’s Chantix/Champix and bupropion drugs.
To find out where the market is heading - both technologically and commercially - from the present onwards.
The majority of smokers worldwide do not have full access to smoking cessation therapies. Smoking prevalence is increasing overall, with increases mainly contributed by developing countries. Adverse health effects and the high economic costs associated with tobacco smoking are encouraging increasingly-stringent smoking legislation and encouraging governmental spending on anti-smoking aids. From 2009 to 2024, the continuing introduction and implementation of tobacco-control policies will accelerate, further encouraging people to stop smoking, in turn increasing the use of smoking cessation products. This report demonstrates how the smoking cessation market will expand worldwide as a result.
Smoking Cessation, 2009-2024 shows that new smoking cessation drugs will enjoy commercial success only if these are clearly tolerable and more-effective in practice, easily accessible, backed by innovative marketing campaigns and delivered in combination with behavioural support programmes. Smoking cessation drugs with these characteristics will overcome regulatory hurdles and achieve adequate reimbursement from cost-conscious healthcare providers.
This report is essential reading for everybody involved in the smoking cessation market, revealing prospects for both existing competitors and potential market entrants, from the present onwards.
(0 items)
